Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Imunon, Inc. (IMNN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq Capital Market issuer. Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies and DNA vaccine technologies, and its filings offer detailed insight into clinical progress, capital structure and listing status.
Current reports on Form 8-K are central for tracking material events. Imunon uses 8-Ks to furnish press releases on quarterly financial results, announce conference calls and webcasts, describe capital markets transactions such as at-the-market equity offerings and registered direct offerings, and report stockholder meeting outcomes. Other 8-Ks document amendments to the Restated Certificate of Incorporation, including increases in authorized common stock and the implementation of a one-for-fifteen reverse stock split, as well as Nasdaq notices regarding minimum bid price and stockholders’ equity requirements and the subsequent confirmation of regained compliance.
Through 8-K items, investors can also follow how Imunon structures its financing, such as prospectus supplements filed under existing shelf registration statements on Form S-3 and the use of sales agents for ATM programs. These filings clarify the legal framework for share issuances and warrant exercises that affect outstanding equity.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when reviewed alongside 8-Ks, provide broader context on clinical programs like IMNN-001 and IMNN-101, risk factors, and research and development spending, although these specific forms are not reproduced in the excerpts here. For insider activity, Form 4 filings would show transactions by directors and officers, complementing the governance information disclosed in proxy-related materials.
On Stock Titan, Imunon filings are updated in near real time from EDGAR, and AI-powered summaries can help explain complex sections of 10-Ks, 10-Qs and 8-Ks in plain language. This allows investors to quickly understand how corporate actions, listing compliance steps and financing decisions intersect with the company’s clinical-stage biotechnology strategy.
Event summary: On August 5, 2025 Imunon, Inc. (IMNN) furnished a press release reporting financial results for the quarter ended June 30, 2025 as Exhibit 99.1. The company had announced on July 29, 2025 that it would hold a conference call on August 5, 2025 to discuss those results; the call was webcast at http://www.imunon.com.
The 8-K clarifies the furnished information is not "filed" under Section 18 of the Exchange Act and contains forward-looking statements subject to a cautionary note in the press release. Exhibits listed are 99.1 (press release) and 104 (Interactive Data). The report is signed by CFO Kimberly Graper and lists principal offices at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311 with phone (609) 896-9100.
Imunon, Inc. filed a Form 8-K on 28 Jul 2025 reporting that its Board of Directors has approved a 15% stock dividend, equal to 0.15 additional shares for every outstanding share and each common-stock equivalent with dividend rights. The Board set 7 Aug 2025 as the record date and 21 Aug 2025 as the payment date. Exhibit 99.1 contains the related press release; no other material events, financial results, or transactions were disclosed. The information in the exhibit is furnished, not filed, under the Exchange Act.
Imunon, Inc. filed a Form 8-K reporting that it amended its Certificate of Incorporation to implement a 1-for-15 reverse stock split of its common stock. The Certificate of Amendment was filed on 21 Jul 2025 and the split becomes effective 25 Jul 2025 at 12:01 a.m. ET.
At the effective time, every fifteen pre-split shares will be combined into one post-split share, reducing the number of outstanding shares from approximately 31.8 million to 2.1 million. Authorized share counts, par value and voting rights remain unchanged. Post-split shares will continue trading on Nasdaq under ticker IMNN with a new CUSIP 15117N701.
No fractional shares will be issued; stockholders otherwise entitled to fractions will receive one whole post-split share. Equiniti Trust Company is the exchange agent. Book-entry holders need not act; broker-held positions adjust automatically. The share reduction is proportionally reflected in all active S-1, S-3 and S-8 registration statements pursuant to Rule 416(b).
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
